BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 2410510)

  • 1. Detection of a neoantigen on human C3bi and C3d by monoclonal antibody.
    Tamerius JD; Pangburn MK; Müller-Eberhard HJ
    J Immunol; 1985 Sep; 135(3):2015-9. PubMed ID: 2410510
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monoclonal antibodies against complement 3 neoantigens for detection of immune complexes and complement activation. Relationship between immune complex levels, state of C3, and numbers of receptors for C3b.
    Aguado MT; Lambris JD; Tsokos GC; Burger R; Bitter-Suermann D; Tamerius JD; Dixon FJ; Theofilopoulos AN
    J Clin Invest; 1985 Oct; 76(4):1418-26. PubMed ID: 2932466
    [TBL] [Abstract][Full Text] [Related]  

  • 3. C3 receptors on human lymphocyte subsets and recruitment of ADCC effector cells by C3 fragments.
    Wåhlin B; Perlmann H; Perlmann P; Schreiber RD; Müller-Eberhard HJ
    J Immunol; 1983 Jun; 130(6):2831-6. PubMed ID: 6222118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Direct quantitation of activated C3 in human plasma with monoclonal anti-iC3b-C3d-neoantigen.
    Kanayama Y; Kurata Y; McMillan R; Tamerius JD; Negoro N; Curd JG
    J Immunol Methods; 1986 Apr; 88(1):33-6. PubMed ID: 2420896
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantification of the complement receptor function on polymorphonuclear leukocytes: its significance in patients with systemic lupus erythematosus.
    Yoshida K; Yukiyama Y; Miyamoto T
    J Rheumatol; 1987 Jun; 14(3):490-6. PubMed ID: 3498035
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interaction of target cell-bound C3bi and C3d with human lymphocyte receptors. Enhancement of antibody-mediated cellular cytotoxicity.
    Perlmann H; Perlmann P; Schreiber RD; Müller-Eberhard HJ
    J Exp Med; 1981 Jun; 153(6):1592-603. PubMed ID: 7252421
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of a monoclonal antibody MoAb bH6 reacting with a neoepitope of human C3 expressed on C3b, iC3b, and C3c.
    Garred P; Mollnes TE; Lea T; Fischer E
    Scand J Immunol; 1988 Mar; 27(3):319-27. PubMed ID: 2451273
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Binding of soluble immune complexes to Raji lymphocytes. Role of receptors for complement components, C1q and C3-C3b.
    Gupta RC; McDuffie FC; Tappeiner G; Jordon RE
    Immunology; 1978 Apr; 34(4):751-61. PubMed ID: 102587
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Three rat monoclonal antibodies to human C3.
    Lachmann PJ; Oldroyd RG; Milstein C; Wright BW
    Immunology; 1980 Nov; 41(3):503-15. PubMed ID: 6161872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Breakdown of C3 after complement activation. Identification of a new fragment C3g, using monoclonal antibodies.
    Lachmann PJ; Pangburn MK; Oldroyd RG
    J Exp Med; 1982 Jul; 156(1):205-16. PubMed ID: 6177820
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of three monoclonal antibodies against C3 with selective specificities.
    Iida K; Mitomo K; Fujita T; Tamura N
    Immunology; 1987 Nov; 62(3):413-7. PubMed ID: 2444528
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of granulocyte histaminase release by particle-bound complement C3 cleavage products (C3b, C3bi) and IgG.
    Melamed J; Medicus RG; Arnaout MA; Colten HR
    J Immunol; 1983 Jul; 131(1):439-44. PubMed ID: 6223078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Generation of three different fragments of bound C3 with purified factor I or serum. II. Location of binding sites in the C3 fragments for factors B and H, complement receptors, and bovine conglutinin.
    Ross GD; Newman SL; Lambris JD; Devery-Pocius JE; Cain JA; Lachmann PJ
    J Exp Med; 1983 Aug; 158(2):334-52. PubMed ID: 6224880
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Determination of complement breakdown fragments C3d and its subfragments in health and disease.
    Tamotsu M; Arai K; Fujita S; Hosotsubo K; Hayashi C; Miyai K; Miyano A; Kawanaka K; Takenaka M; Shimizu A
    Diagn Immunol; 1984; 2(2):116-21. PubMed ID: 6333963
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of monoclonal anti-C3 antibodies to characterise the fragments of C3 that are found on erythrocytes.
    Lachmann PJ; Voak D; Oldroyd RG; Downie DM; Bevan PC
    Vox Sang; 1983; 45(5):367-72. PubMed ID: 6605620
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Binding of C3 fragments to the Trypanosoma cruzi surface in the absence of specific antibodies and without activation of the complement cascade.
    Krettli AU; Pontes de Carvalho LC
    Clin Exp Immunol; 1985 Nov; 62(2):270-7. PubMed ID: 3910312
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disease-associated loss of erythrocyte complement receptors (CR1, C3b receptors) in patients with systemic lupus erythematosus and other diseases involving autoantibodies and/or complement activation.
    Ross GD; Yount WJ; Walport MJ; Winfield JB; Parker CJ; Fuller CR; Taylor RP; Myones BL; Lachmann PJ
    J Immunol; 1985 Sep; 135(3):2005-14. PubMed ID: 4020137
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Generation of low m.w., C3-bearing immunoglobulin in human serum.
    Jacobs RJ; Reichlin M
    J Immunol; 1983 Jun; 130(6):2775-81. PubMed ID: 6602181
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation of C3d fixing circulating immune complexes with disease activity and clinical parameters in patients with systemic lupus erythematosus.
    Sekita K; Doi T; Muso E; Yoshida H; Kanatsu K; Hamashima Y
    Clin Exp Immunol; 1984 Mar; 55(3):487-94. PubMed ID: 6608422
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantification by ELISA of erythrocyte-bound C3 fragments expressing C3d and/or C3c epitopes in patients with factor I deficiency and with autoimmune diseases.
    Møller Rasmussen J; Jepsen HH; Teisner B; Holmskov-Nielsen U; Rasmussen GG; Svehag SE
    Vox Sang; 1989; 56(4):262-9. PubMed ID: 2474900
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.